Pembrolizumab with sacituzumab govitecan instead of chemotherapy led to improved progression-free survival in PD-L1-postive ...

The treatment could also delay the need for gruelling chemotherapy, according to the trial. | ITV National News ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an ...

PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...

There’s a worrying trend in the cancer world with young adults getting cancer at higher rates, and scientists don’t know why.

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

Scientists at St. Jude Children's Research Hospital have found that genetics and type of cancer treatment contribute most to ...

Bob Segert is the chairman and CEO of athenahealth, a technology company offering electronic health records, revenue cycle ...